Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lebrikizumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Lebrikizumab. Displaying page 1 of 1.
    EudraCT Number: 2013-001163-24 Sponsor Protocol Number: GB28547 Start Date*: 2013-11-04
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS.
    Medical condition: IDIOPATHIC PULMONARY FIBROSIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed) PL (Completed) GB (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004218-41 Sponsor Protocol Number: GB27862 Start Date*: 2012-06-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second ...
    Medical condition: Uncontrolled asthma despite the use of an inhaled corticosteroid and a second controller medication.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) SK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004205-24 Sponsor Protocol Number: GB27864 Start Date*: 2012-09-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second ...
    Medical condition: Uncontrolled asthma despite the use of an inhaled corticosteroid and a second controller medication.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000275-14 Sponsor Protocol Number: GB29260 Start Date*: 2014-08-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II, randomized, double-blind, placebo-controlled bronchoscopy study to evaluate the effects of Lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhal...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000180-25 Sponsor Protocol Number: WB28183 Start Date*: 2013-09-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma who are on inhaled co...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) PT (Completed) HU (Completed) IT (Prematurely Ended) CZ (Completed) ES (Completed) PL (Completed) GB (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-001122-42 Sponsor Protocol Number: WB29804 Start Date*: 2015-10-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with chronic obstructive pulmonary disease and a history of exacerbations
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000176-15 Sponsor Protocol Number: GB28689 Start Date*: 2013-11-20
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, randomized, double-blind, placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a secon...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) HU (Completed) IT (Prematurely Ended) CZ (Completed) ES (Completed) PL (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-013267-19 Sponsor Protocol Number: ILR4660g Start Date*: 2009-10-16
    Sponsor Name:GENENTECH, Inc.
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE LEBRIKIZUMAB (MILR1444A) IN ADULT PATIENTS WITH ASTHMA WHO ARE NOT TAKING INHALED CORTICOSTEROIDS (MOLLY)
    Medical condition: Asthma in adult patients not taking inhaled corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    12.0 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-004625-81 Sponsor Protocol Number: WA29249 Start Date*: 2014-08-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA.
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) GB (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000190-24 Sponsor Protocol Number: WB28182 Start Date*: 2013-11-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO ASSESS THE ORAL CORTICOSTEROID–SPARING EFFECT OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE CORTICOSTEROID-DEPENDENT ASTHMA.
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) BE (Completed) SK (Completed) SI (Completed) NL (Completed) PL (Completed) BG (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000175-33 Sponsor Protocol Number: GB28688 Start Date*: 2013-09-04
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, randomized, double-blind, placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a secon...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) BE (Completed) GB (Completed) HU (Completed) IT (Prematurely Ended) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-010359-28 Sponsor Protocol Number: ILR4646g Start Date*: 2012-05-30
    Sponsor Name:Genentech, Inc
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF LEBRIKIZUMAB (MILR1444A)IN ADULT PATIENTS WITH ASTHMA WHO ARE INADEQUATELY CONTRO...
    Medical condition: Asthma in patients who are inadequately controlled by inhaled corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-000049-56 Sponsor Protocol Number: GS29250 Start Date*: 2015-05-29
    Sponsor Name:F. Hoffmann-la roche Ltd
    Full Title: A phase II, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequat...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) FI (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002932-10 Sponsor Protocol Number: DRM06-AD04 Start Date*: 2020-03-06
    Sponsor Name:Dermira, a wholly owned subsidiary of Eli Lilly and Company
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) PL (Completed) EE (Completed) FR (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-002933-12 Sponsor Protocol Number: DRM06-AD05 Start Date*: 2020-10-12
    Sponsor Name:Dermira, a wholly owned subsidiary of Eli Lilly and Company
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002967-23 Sponsor Protocol Number: M-17923-30 Start Date*: 2022-01-27
    Sponsor Name:Almirall, S.A.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients ...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) PL (Completed) BE (Completed) IT (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004301-28 Sponsor Protocol Number: DRM06-AD17 Start Date*: Information not available in EudraCT
    Sponsor Name:Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company
    Full Title: AN OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001211-24 Sponsor Protocol Number: DRM06-AD07/J2T-DM-KGAA Start Date*: Information not available in EudraCT
    Sponsor Name:Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company
    Full Title: A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) DE (Completed) LV (Completed) LT (Completed) EE (Completed) FR (Completed) BG (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004300-34 Sponsor Protocol Number: DRM06-AD06 Start Date*: Information not available in EudraCT
    Sponsor Name:Dermira, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN USED IN COMBINATION WITH TOPICAL CORTICOSTEROID TREATMENT IN PATIENTS WITH MODERATE-TO-...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 02:48:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA